Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation
Open Access
- 10 November 2011
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 18 (6) , 913-921
- https://doi.org/10.1016/j.bbmt.2011.10.041
Abstract
No abstract availableKeywords
Funding Information
- Genzyme Corp
- Genzyme Corporation
This publication has 46 references indexed in Scilit:
- Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicityLeukemia & Lymphoma, 2011
- Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDSBone Marrow Transplantation, 2011
- T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapseLeukemia & Lymphoma, 2010
- Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International WorkshopBlood, 2010
- Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2009
- Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative ConditioningTransplantation and Cellular Therapy, 2008
- A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasBlood, 2007
- Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin’s lymphoma (NHL)Transfusion and Apheresis Science, 2005
- Cardiac toxicity of high-dose chemotherapyBone Marrow Transplantation, 2004
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989